SOURCE: Research and Markets

Research and Markets

February 17, 2016 07:26 ET

Future Opportunities in the Global Protein Expression Systems Market With Current Landscape Insights

Study Identifies Over 160 Biopharmaceutical CMOs

DUBLIN, IRELAND --(Marketwired - February 17, 2016) - RESEARCH and MARKETS has announced the addition of the "Protein Expression Systems Market: Current Landscape and Future Opportunities" report to their offering.

The highly lucrative biologics market presents a huge opportunity for such systems. Both large and small companies in this sector have developed proprietary recombinant protein expression techniques to carve out their own share of the multi-billion dollar market. The increasing demand for biologics has led to the involvement of various CMOs providing services in protein expression. However, there are some technical shortcomings in current platforms which need to be dealt with to maximize the available opportunity. The opportunity, overall, will continue to increase manifold with the approval of several new biologics and biosimilars in the coming few years.

The "Protein Expression Systems Market: Current Landscape and Future Opportunities" report provides an extensive study of the various expression systems commercially available for the purpose of expressing the desired proteins. Selecting an effective and reliable expression system is one of the pre-requisites for pharma companies before they start proof of concept studies for biological molecules. It is well known that a particular expression system is not suitable to express every kind of protein. As such, there are several different types of platforms available to meet the growing demand.

With an extensive pipeline of biologic drugs, protein expression systems are likely to continue to garner significant attention from the biopharmaceutical industry. The report covers various aspects such as key features of these systems, associated products, licensing and services portfolio. We have also covered specific details on CMOs manufacturing biopharmaceutical products highlighting their capabilities, geographical location, scale of operation, type of biologics being manufactured and expression systems being used.

In addition, the report highlights the future growth prospects with respect to manufacturing biological molecules. The report has analyzed the overall biologics pipeline and provided specific details on some important classes such as antibody drug conjugates (ADCs) and bispecific antibodies. In addition, the emerging opportunity presented by the ongoing development of biosimilars has been highlighted. For the purposes of the study, important stakeholders were interviewed to solicit their opinions around the upcoming opportunities and challenges which must be considered for a more inclusive growth. Examples of companies interviewed include Research Corporation Technologies, iBio and Jena Bioscience.

Sample Highlights

- Presently bacterial and mammalian cell based systems are the preferred choice for therapeutic protein expression. Bacterial systems are preferred for their low cost, high productivity and rapid results. Mammalian cells, on the other hand, have the ability to generate proteins with folding and post-translational modification identical to native endogenous protein.

- A number of new host systems have come into the market offering advantages such as higher protein yield, diminishing susceptibility to viral contamination and easy scale up. Among these are yeast, insect, and also certain plant based protein expression systems. Cell free systems have also gained momentum and allow direct manipulation of the chemical environment that rapidly generates significant amounts of the required protein.

- In addition to the well-established firms such as Agilent Technologies, Clontech, Life Technologies, Lonza, Merck Millipore, Promega Corporation and Research Corporation Technologies, several smaller companies too have developed robust proprietary expression systems. Examples (in alphabetic order) include Dyadic International, Geneva Biotech, Greenovation, iBio, Jena Bioscience, New England Biolabs, Oxford Expression Technologies, Pfenex and Scarab Genomics.

- The highly lucrative biologics market presents a huge opportunity for protein expression systems. The biologics market is considered to be worth over USD 200 billion and has an increasing number of therapeutically relevant protein based molecules in the pipeline.

- The outlook for CMOs is highly promising. The stud identified over 160 biopharmaceutical CMOs (accounting for over 250 production facilities worldwide), which provide protein expression services. With around 900 biologics in the pipeline and 150 marketed products, CMOs stand to benefit tremendously from this growing trend.

- Technological improvements including the use of highly evolved expression elements such as designer promoters for obtaining higher translational efficiency, genome engineering to facilitate better homologous recombination and computer-controlled feeding algorithms are likely to further maximize output and yield.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Expression Systems: Key Features and Products

6. Company Profiles

7. CMO Services

8. Opportunity Analysis

9. SWOT Analysis

10. Interview Transcripts

11. Conclusion

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organizations

Companies Mentioned

- 3P Biopharmaceuticals
- AAIPharma Services
- AbbVie
- AbGenomics
- Abnova
- AdAlta
- ADC Therapeutics
- Aeras
- Affinicon
- Affinity Life Sciences
- Agilent Technologies
- Ajinomoto Althea
- Aldevron
- Allele Biotechnology
- Alliance Medical Products (Siegfried)
- Alpax Pharmaceuticals
- Ambrx
- AMEGA Biotech
- AMYRA Biotech
- Apotex Fermentation
- Aragen Bioscience
- Artes Biotechnology
- Asahi Glass Co.
- Astellas
- AthenaES
- AutekBio
- Avecia
- Avesta Biotherapeutics and Research
- Avid Bioservices
- Batavia Bioservices
- Bavarian Nordic
- Baxter BioPharma Solutions
- Bayer Healthcare
- BD Biosciences
- Bharat Biotech
- Binex Co.
- Bio Elpida
- BioCision
- Bio-Concept
- BioConnection
- BioConvergence
- BioGenomics
- BioGrammatics
- Bioinformatics
- BioIngenium
- Biomay
- Bioneer
- Frederick National Laboratory for Cancer Research (FNLCR)
- BioPharmaceuticals Australia
- Bio-Rad Laboratories
- BioReliance
- BioSavita
- BioSynergy
- Biotechnique
- Biotechpharma
- Biotest
- BioVectra
- Biovest International
- Biovian
- Biovolutions
- BioXcellence (Boehringer Ingelheim)
- Bristol Myers Squibb
- BroadOak Capital Partners
- Cantab Biopharmaceuticals
- Catalent
- Catalyst biosciences
- Cellca
- Celldex Therapeutics
- CellFree Sciences
- Celgene
- Celonic
- Center for Biocatalysis and Bioprocessing, The University of Iowa
- Cerbios-Pharma
- CEVEC Pharmaceuticals
- ChemPartner
- Cilian
- Clontech (a Takara Bio Company)
- CMC Biologics
- Cobra Biologics
- Cognate BioServices
- Concord Biotech
- Cook Pharmica
- Creative Biolabs
- Crucell
- Cytovance Biologics
- Dalton Pharma Services
- Development Center for Biotechnology, Taiwan
- DisperSol technologies
- DM BIO DONG-A meiji
- Dow Pharma
- Dyadic International
- Emergent BioSolutions
- Enteris BioPharma
- Esperance Pharmaceuticals
- EUCODIS Bioscience
- Eurogentec
- Florida Biologix
- Formation Biologics
- FUJIFILM Diosynth Biotechnologies
- Fujirebio Europe
- Gala Biotech (Catalent subsidiary)
- GeneCopoeia
- Geneva Biotech
- Genhelix (mAbxience group)
- Genmab
- GlaxoSmithKline Biopharmaceuticals
- Glide Pharma
- Glycotope Group
- Gold Standard Diagnostics
- Goodwin Biotechnology
- Grand River Aseptic Manufacturing
- GTP Technology
- Hisun Pharmaceuticals USA
- Hong Kong Institute of Biotechnology
- Hospira One 2 One
- iBIO
- IDT Biologika
- Inno Biologics
- Innovent Biologics
- Intas Pharmaceuticals
- Integrity Bio
- Intrexon
- Irvine Pharmaceutical Services
- Jena Bioscience
- Jenrin Discovery
- KABS Pharmaceutic Services
- Kairos Therapeutics
- KBI BioPharma
- Kemwell Biopharma
- Kentucky BioProcessing
- Lampire Biological Laboratories
- Leinco Technologies
- LFB Biomanufacturing
- Life Technologies
- LifeSensors
- Lonza
- Lucigen
- Lyophilization Services of New England.
- Mabion
- Maine Biotechnology Services
- MassBiologics
- MBI International
- Medicago
- Memorial Sloan-Kettering Cancer centre
- Menarini Biotech
- Merck KGaA
- Merck Millipore
- Merck Serono
- Meridian Life Science
- Miltenyi Biotec
- MoBiTec
- Mycenax Biotech
- Neuland Laboratories
- New England Biolabs
- Nextar Chempharma Solutions
- Norwegian Institute of Public Health
- Nova Laboratories
- Novasep
- Novozymes
- OctoPlus
- Omnia Biologics
- Orflo Technologies
- OsoBio (AMRI)
- Oxford Expression Technologies
- PacificGMP
- Paragon Bioservices
- Patheon (unit of DPx Holdings)
- Pfizer CentreSource
- PharmaSynth
- Pharmedartis
- Phyton Biotech
- Piramal Pharma Solutions
- Plant BioScience
- Plasmid Factory
- Polymun Scientific
- Premas Biotech
- ProBioGen
- ProteoNic
- Progenitor Cell Therapy
- ProMab Biotechnologies
- Promega Corporation
- Protalix Biotherapeutics
- Provantage Biodevelopment Center
- PX'Therapeutics
- PYRAMID Laboratories
- QuaDPharma
- Reliance Life Sciences
- Rentschler Biotechnologie
- Research Corporation Technologies
- Rhein Biotech
- Richter-Helm BioTec
- RiNA
- Samsung BioLogics
- Sandoz
- Sanofi Pasteur
- Sanofi CEPiA
- Sanquin Pharmaceutical Services
- Scarab Genomics
- Scil Proteins
- Shasun
- SICOR Biotech (Teva)
- Sigma-Aldrich Corporation
- Sinocelltech
- Statens Serum Institut
- Strides Arcolab
- Sutro Biopharma
- Symbiosis Pharmaceutical Services
- SynCo Bio Partners
- Syngene (Subsidiary of Biocon)
- Synthon
- Sypharma
- Tetragenetics
- Teva Pharmaceuticals
- Therapure Biopharma
- Thermo Fisher Scientific
- Toyobo Biologics
- Trenzyme
- University of California, San Francisco (UCSF)
- University of Nebraska
- Valneva
- Vetter Pharma International
- Vibalogics
- Vista Biologicals Corp.
- Vivalis SA
- VTU Technology
- Wacker Biotech
- Waisman Biomanufacturing
- Wockhardt
- WuXi AppTec
- Xbrane Bioscience
- Xcelience
- Zhejiang Medicine Co.
- Zymeworks

For more information visit

Research and Markets

Sector: Proteomics

Contact Information

  • Laura Wood
    Senior Manager
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716